Here's what I heard;
Partnership with European IMPL will fully fund EMA clinical trials, they will produce antibodies and shouldn't cost us a penny. We should obtain FDA approval/recognition soon after. Keep in mind that a lot of the leg work was already done through the Bulgarian FDA so we won't have to repeat many steps.
BigPharma is encouraging us and our technology. Even though we have proof concept they want to see milestones. Perhaps the INSERIM (Strousbourg University) test results is a key milestone, Perhaps its the animal trials.
We can expect $100B in earnings from Just Clone 3 in the HIV in 11 years of sales. This does NOT include potentially other product development for other viruses. Also, earnings is profit (revenue - cost) so revenue is likely > $200B in 11 years for just HIV. This does not include any licensing fees, or COVID mAb/vaccine.
And yeah, commercializing a drug will take time BUT this is a biopharma play. All we need is buy-in from BigPharma to legitimize and secure our revenue projections and share value will come to the stock well before the company generates a $1 in revenue.
Heck, we could license the technology tomorrow and start generating revenue. Let's not forget the $50MM Contract value from neutraceutical spray which wasn't even on our radar.
AI
Market Data 
Markets 
